| |AUGUST 20268TOP STORIESAMYLYX DRUG CUTS DANGEROUS LOW BLOOD SUGAR EPISODES BY 55 PERCENTINDIAN SKINCARE ENTERS A NEW HORIZON WITH WIPRO'S DERMATOUCH DEALTENET DIAGNOSTICS GETS USD 30 MILLION BOOST FROM TATA CAPITALINDIA PREPARES ITS HEALTHCARE WORKFORCE FOR THE GLOBAL MARKETPIRAMAL PHARMA BUILDS A STRONGER VACCINE CDMO PLATFORMAmylyx Pharmaceuticals' low blood sugar drug avexitide has delivered strong results in a late-stage trial. The experimental treatment cut hypoglycemic episodes by 55 percent versus placebo. The results came from a 78-patient trial involving people who had undergone weight-loss surgery.The trial met its main goal after 16 weeks. The results also pushed Amylyx shares more than 45 percent higher during Tuesday trading. The stock reached USD 31.72 in morning trading. The jump could add about USD 1.15 billion to the company's market value.Indian skincare is entering a new growth phase as established consumer companies move deeper into premium and science-backed beauty. Wipro Consumer Care & Lighting's acquisition of Dermatouch marks a major step in this direction.Wipro will initially acquire a 60 per cent stake in the Ahmedabad-based skincare brand and take the remaining 40 per cent over three years. The deal gives Wipro its first digital-first brand and a direct entry into India's premium skincare segment. The transaction also highlights growing corporate interest in India's fast-expanding dermal and specialized skincare categories.Tenet Diagnostics has received a major USD 30 million investment from Tata Capital Healthcare Fund III and Swiss impact investor Blue Earth Capital AG. The deal marks a fresh push into India's growing diagnostics market. The investment will help Tenet Diagnostics expand its presence and strengthen its laboratory network.The investment was made in Tenet Medcorp, the company operating under the Tenet Diagnostics brand. The transaction involves an undisclosed equity stake. It is also among the first investments by Tata Capital Healthcare Fund III after its first close earlier this year.India's healthcare workforce is gaining a new pathway to international careers. OET and the International Institute of Medical Science and Technology Council (IIMSTC) have joined forces to support this goal. The partnership will strengthen communication skills among Indian healthcare professionals. It will also prepare them for international healthcare systems.Countries such as the UK, Australia, New Zealand and Ireland face healthcare workforce shortages. They continue to seek qualified professionals. OET will bring its healthcare-specific language expertise, while IIMSTC will provide its institutional network. The partnership will focus on educational programs, workshops, faculty engagement and knowledge-sharing initiatives.CDMO platform expansion is gaining momentum at Piramal Pharma as the company takes majority control of Yapan Bio. Piramal Pharma has acquired an additional 40.67 per cent stake for Rs 76 crore, raising its ownership from 33.33 per cent to 74 per cent.The transaction turns Yapan Bio into a subsidiary and strengthens Piramal Pharma's capabilities in vaccine and biologics development. Yapan operates as a specialized CDMO focused on process development, characterization and Phase I/II GMP manufacturing.
< Page 7 | Page 9 >